《蓝筹业绩》万洲国际(00288.HK)首季生物公允价值调整前纯利跌17%至2.93亿美元
万洲国际(00288.HK)公布截至今年3月底止首季业绩,生物公允价值调整前收入66.1亿美元(下同),按年升5.2%。纯利2.93亿元,按年跌17%;每股盈利1.99仙。
按生物公允价值调整後计算,纯利则按年升81.9%至5.11亿元,每股盈利录3.47仙。期内肉制品上升7.3%至83.8万公吨,猪肉销量升7.2%至101万公吨。公司表示,将继续实行有关扩产上量、调整产品结构及提高效率的经营策略,认为猪肉为消费必需品,加上公司拥有垂直整合和地域多元化的优势,预期将可以有效应对挑战,并达至持续增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.